2010

  • Peter George forms the Clinigen Group by bringing together Clinigen, Clinigen Healthcare and Keats Healthcare
  • Clinigen acquires its first product, Foscavir and commences Global Access Programs supplying unlicensed medicines globally
  • Employees: 32

2011

  • Clinigen recognised as the fastest-growing private company in the UK by the Sunday Times Virgin Fast Track 100
  • Employees: 48

2012

  • Clinigen moves warehousing into brand new Operations Centre
  • Clinigen lists on the Alternative Investment Market (AIM) of the London Stock Exchange – the first UK healthcare company to list in London in five years
  • Employees: 72

2013

  • Clinigen marks its first year as a public company by winning Best Newcomer at the London Stock Exchange AIM Awards
  • Clinigen wins IPO of the Year at the 2013 M&A Awards
  • Clinigen SP acquires its second product, Cardioxane
  • Employees: 101

2014

  • Clinigen opens new, extended headquarters in Burton-on-Trent, UK
  • Clinigen acquires its third product, Savene
  • Clinigen acquires its fourth product, Ethyol
  • Peter George wins Chief Executive of the Year at 2014 European Mediscience Awards
  • Clinigen launches its new web portal, Cliniport, which allows healthcare professionals to order products directly via the internet
  • Employees: 116

2015

  • Clinigen acquires Idis in April 2015 to become the global leader in providing ethical compliant access to unlicensed medicines
  • Clinigen acquires Link Healthcare in October 2015 to expand its ability to provide access to medicines for patients in the Africa, Asia and Australia regions
  • Clinigen awarded the ServiceMark accreditation by The Institute of Customer Service, in recognition of the Group’s commitment to, and achievement in, customer services
  • Employees: 450

2016

  • Launch of Japanese business, Clinigen KK, with Foscavir as its first product
  • Clinigen acquires its fifth product, Totect US, completing the global dexrazoxane portfolio
  • Clinigen continues Foscavir development with purchase of a new bag presentation
  • Clinigen launches Ethyol in the US in partnership with Cumberland Pharma
  • Shaun Chilton replaces Peter George as Chief Executive Officer of Clinigen Group plc
  • Employees: 530

2017

  • Clinigen receives investors in people silver award
  • Clinigen receives EC approval for updates to Cardioxane product information
  • Clinigen launched Totect in the US in partnership with Cumberland Pharma
  • Clinigen acquires IMMC, Japan’s largest supplier of unlicensed medicines
  • Clinigen acquires Quantum Pharma plc in November 2017 extending its Unlicensed Medicines capability and accelerating its unlicensed to licensed global strategy
  • Employees: 849

2018

  • Clinigen signs extended partnership agreement with Bristol-Myers Squibb to supply its portfolio of products in South Africa
  • Clinigen acquires its sixth product, Proleukin (global rights outside the US)
  • Clinigen acquires its seventh product, Imukin (global rights outside the US, Canada and Japan)
  • Clinigen acquires CSM a specialist provider of packaging, labelling, warehousing and distribution services with infrastructure in the US, Belgium and Germany
  • Clinigen acquires iQone, a Swiss-based specialty pharmaceutical business providing EU medical scientific liaison (MSL) capability
  • Employees: 1,182

2019

  • Clinigen acquires the US rights to Proleukin